Clinical Trials

Colorectal Cancer, Gynecological Cancers, Pancreatic Cancer, Prostate Cancer, Breast Cancer
PROgram to address psychosocial Support, clinical outcomes, and genomic insights for Patients with EaRly onset cancers
Phase 1 Cancers
Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)
Phase 1 Cancers
Open-label Dose-finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients With Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroesophagealjunction Adenocarcinoma
Lung Cancer
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
Colorectal Cancer, Gynecological Cancers, Stomach and Esophagus, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Lymphoma, Thyroid and Other Endocrine Cancers, Other Cancers, Pancreatic Cancer, Prostate Cancer, Phase 1 Cancers, Breast Cancer, Bladder Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Phase 1 Cancers
First-In-Human, Open-Label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects With Malignant Solid Tumors
Phase 1 Cancers
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Phase 1 Cancers
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma
Phase 1 Cancers
A Phase I Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Gynecological Cancers
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
- GenderFemale only